Modified Lincosamide Antibiotics for Resistant Pathogen Selectivity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Emerging resistance to existing antibiotics, particularly in Gram-negative bacteria, necessitates the development of new lincosamide antibiotics that are effective against drug-resistant pathogens and minimize adverse effects on commensal gut flora, such as Clostridium difficile-associated diarrhea.

Innovation Solution

A synthetic platform for producing lincosamides with unprecedented modifications to the aminooctose and amino-acid portions, enhancing their activity against resistant strains of S. aureus, S. pneumoniae, E. faecalis, and E. coli, while reducing impact on gut flora.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If lincosamide antibiotics are used to treat bacterial infections, then antibacterial activity is improved, but resistance development and adverse effects on gut flora worsen

Engineering Contradiction:

Improveantibacterial activityVSAvoidresistance development and gut flora damage

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies parameter changes by systematically modifying chemical parameters of the lincosamide structure, specifically at positions 4, 6, and 7 of the clindamycin core. These structural parameter changes create new derivatives with altered binding characteristics that maintain antibacterial activity while reducing resistance development and gut flora damage.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent applies local quality by introducing specific substituents at localized positions (4, 6, and 7) of the lincosamide molecule rather than uniformly modifying the entire structure. This allows targeted optimization of binding affinity and selectivity at specific regions while preserving overall molecular function.

Inventive Principle:

Principle #3Local quality

2Reliability

If existing lincosamides like clindamycin are used, then treatment of Staphylococcus and Streptococcus infections is effective, but pseudomembranous colitis and C. difficile-associated diarrhea occur

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidpseudomembranous colitis and C. difficile-associated diarrhea

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent modifies chemical parameters at positions 4, 6, and 7 of the clindamycin structure to create derivatives that selectively enhance activity against pathogenic bacteria while reducing impact on commensal gut flora, thereby decreasing the risk of C. difficile-associated diarrhea and pseudomembranous colitis.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent converts the harmful broad-spectrum activity of clindamycin that damages gut flora into a beneficial selective activity by introducing substituents that specifically enhance binding to resistant pathogens while sparing commensal bacteria, thus transforming a harmful side effect into a therapeutic advantage.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Reliability

If bacteria undergo methylation of the 23s binding site, then resistance to macrolides and lincosamides develops, but this resistance mechanism limits treatment options

Engineering Contradiction:

Improvebinding affinityVSAvoidresistance mechanism

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies local quality by introducing substituents at specific positions (4, 6, and 7) of the lincosamide molecule that create localized structural differences, allowing these derivatives to maintain binding affinity despite methylation of the 23s binding site in resistant bacteria.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent changes structural parameters of the lincosamide molecule to create derivatives that can accommodate or overcome the methylation modification in resistant bacteria, thereby maintaining binding affinity and activity against strains that have developed resistance through ribosomal methylation.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The modified lincosamides demonstrate potent activity against high-priority pathogens and reduced adverse effects, offering safer alternatives to clindamycin with increased efficacy against resistant bacteria and C. difficile.

Implementation Method 1

They bind to the 23s portion of the 50S subunit of bacterial ribosomes and cause premature dissociation of the peptidyl-tRNA from the ribosome

Methodology Applied

Scientific EffectRibosomal binding:

Data Source

PatentEP3664799B1Lincosamide antibiotics and uses thereof

Publication Date: 2025.10.01 PRESIDENT & FELLOWS OF HARVARD COLLEGE

AI summary

Provided are lincosamide compounds for the treatment of infectious diseases. The lincosamides described herein are modified at the amino acid (southern) region. The lincosamides may have further modification at the C-1 and C-7 positions of the aminooctose (northern) region, thus distinguishing them from lincomycin and clindamycin. Also provided are methods for preparing the lincosamide compounds, pharmaceutical compositions comprising the lincosamide compounds, and methods of treating infectious diseases using the disclosed lincosamide compounds.